the aid library

LIST OPTIONS

Filter

5873

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (78)

View PDF (92)

Improving the global diagnosis and management of asthma in children

Lenney, W.; Bush, A.; Fitzgerald, D.A. et al. BMJ Journals (2018) CC

Asthma is the most common chronic condition in children worldwide. It affects daytime activities, sleep and school attendance and causes anxiety to parents, families and other carers. The quality of asthma diagnosis and management globally still needs substantial improvement. From infancy to the tee... more

Download (260)

View PDF (305)

Therapeutics and COVID-19: living guideline, Updated 16 September 2022
recommended

World Health Organization WHO (2022) C_WHO

This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients wi... more

Download (282)

View PDF (272)

Psychological interventions in adults and children with epilepsy

World Health Organization WHO (2012) C_WHO

Q 10: In adults and children with epilepsy, which psychological interventions used as adjunctive therapies with antiepileptic drugs when compared to placebo/comparator produce benefits/harm in specified outcomes?

Download (890)

View PDF (1477)

Guidelines on the treatment of skin and oral HIV-associated conditions in children and adults

World Health Organization WHO (2014) C_WHO

Skin and mucosal conditions are extremely common in all children and adults in particular in HIV-infected adults and children and are one of the commonest daily management problems faced by health care workers caring for patients with HIV infection

Download (185)

View PDF (214)

Заболевание COVID-19 у детей и подростков Научная справка 29 сентября 2021 г.

World Health Organization WHO (2021) C_WHO

SARS-CoV-2 infections among children and adolescents cause less severe illness and fewer deaths compared to adults. While a less severe course of infection is a positive outcome, there are concerns that mild symptoms may have led to less testing, resulting in fewer identified cases of COVID-19 in ch... more

Download (1574)

View PDF (1962)

PIH Guide to the Medical Management of MDR-TB

USAID; TB Care; DRTB Training Network (2014) C1

This guide is a resource for physicians and other health care professionals who provide care and treatment to patients with drug-resistant tuberculosis.

Download (356)

View PDF (348)

Guidance for commissioners of older people’s mental health services

Joint Commissioning Panelfor Mental Health (2013) C2

This guide has been written to provide information and practical advice on developing and delivering local plans an strategies to commission the most effective and efficient older people’s mental health services.Based upon clinical best practice guidance and drawing upon the range of available evi... more

Download (286)

View PDF (328)

Clinical management and infection prevention and control for monkeypox
recommended

World Health Organization WHO (2022) C_WHO

Interim rapid response guidance, 10 June 2022. It includes considerations for certain populations such as patients with mild disease with considerations for community care, patients with moderate to severe disease, sexually active persons, pregnant or breastfeeding women, children and young persons... more

External Link

Financing HIV Programming: How Much Should Low And Middle-Income Countries and their Donors Pay?

Galarraga, O.; V. J. Wirtz; Y. Santa-Ana-Tellez et al. PLOS One (2013) C1

Global HIV control funding falls short of need. To maximize health outcomes, it is critical that national governments sustain reasonable commitments, and that international donor assistance be distributed according to country needs and funding gaps. We develop a country classification framework in t... more

Download (618)

View PDF (381)

Hypertension Management Program (HMP) Toolkit

Centers for Disease Control and Prevention (CDC) (2021) C_CDC

This toolkit was developed by the Centers for Disease Control and Prevention (CDC) Division for Heart Disease and Stroke Prevention (DHDSP) to provide healthcare organizations, including those in resource-constrained settings, with the information and resources to implement the HMP and improve hyper... more

Download (158)

View PDF (203)

Communicable Diseases: Part 4 Other Diseases of Public Health Importance and Surveillance.

HEAT, UNICEF, Open University, AMREF Ministry of Health, Federal Democratic Republic of Ethiopia (2015) C1

Blended Learning Modulef or the Health Extension Programme In this study session, you will learn about the general features of faeco-oraldiseases: the main types commonly found in Ethiopia, their general symptomsand signs, how to treat mild cases and when to refer patients with severeconditions for... more

Download (129)

View PDF (107)

Monitoring asthma in children

Pijnenburg, M.W.; Baraldi, E.; Brand, P.L. et al. European Respiratory Journal (2015) CC

The goal of asthma treatment is to obtain clinical control and reduce future risks to the patient. To reach this goal in children with asthma, ongoing monitoring is essential. While all components of asthma, such as symptoms, lung function, bronchial hyperresponsiveness and inflammation, may exist i... more

Download (650)

View PDF (785)

Second WHO Model List of Essential In Vitro Diagnostics

World Health Organization WHO (2019) C_WHO

The updated List of Essential Diagnostics contains 46 general tests that can be used for routine patient care as well as for the detection and diagnosis of a wide array of disease conditions, and 69 tests intended for the detection, diagnosis and monitoring of specific diseases. The List is divid... more

Download (201)

View PDF (237)

Efficacy and Safety of Pafuramidine versus Pentamidine Maleate for Treatment of First Stage Sleeping Sickness in a Randomized, Comparator-Controlled, International Phase 3 Clinical Trial

Pohlig G, Bernhard SC, Blum J, Burri C, Mpanya A, et al. PLOS Neclected Tropical Diseases (2016) CC

This was a Phase 3, multi-center, randomized, open-label, parallel-group, active control study where 273 male and female patients with first stage Trypanosoma brucei gambiense HAT were treated at six sites: one trypanosomiasis reference center in Angola, one hospital in South Sudan, and four hospita... more

Download (134)

View PDF (184)

Rehabilitation considerations during the COVID-19 outbreak

Pan American Health Organization PAHO, World Health Organization WHO (2020) C_WHO

Severe cases of COVID-19 are associated with rehabilitation needs related to the consequences of ventilatory support, and prolonged immobilization and bed rest. These may include: − Impaired lung function; − Physical deconditioning and muscle weakness; − Delirium and other cognitive impairment... more

Download (197)

View PDF (206)

Strengthening countries’ capacities to adopt and adapt evidence-based guidelines: a handbook for guideline contextualization

World Health Organization WHO (2023) C_WHO

Trustworthy, evidence-based health guidelines form the basis of national policies affecting both patients and health-care workers. Emphasizing the link between robust evidence and people’s trust in their health systems, Dr Hans Henri P. Kluge, WHO Regional Director for Europe said at the launch ev... more

Download (1316)

View PDF (1000)

The National Tuberculosis Health Sector Strategic Plan 2015-2020
recommended

Bonsu FA, Hanson-Nortey NN, Afutu FK et al. Ghana, Ministry of Health (2014) C1

The mandate of the National Tuberculosis Control Programme is to provide leadership and stewardship to accelerate intense and coordinated efforts to reduce the adult TB burden of 290 per 100,000 population recently established in the 2013 National TB Prevalence Survey. Other key challenges are low T... more

External Link

Testing for Ethnic Discrimination in Outpatient Health Care: Evidence from a Field Experiment in Germany

M. Halla; Kah, C.; Sausgruber, R. Johannes Kepler University Linz (2022) CC

To test for ethnic discrimination in access to outpatient health care services, we carry out an email-correspondence study in Germany. We approach 3,224 physician offices in the 79 largest cities in Germany with fictitious appointment requests and randomized patients’ characteristics. We find t... more

Download (79)

View PDF (106)

Polio transition strategic framework: monitoring and evaluation

World Health Organization WHO (2024) C_WHO

The Polio Transition1 Monitoring and Evaluation (M&E) Framework was designed to monitor progress towards achieving the strategic and operational outcomes of the post-2023 Strategic Action Plan on Polio Transition (2018– 2023), as outlined in the Global Vision to use polio investments to build st... more

Therapeutics and COVID-19: living guideline, Updated 16 September 2022 recommended

Clinical management and infection prevention and control for monkeypox recommended

The National Tuberculosis Health Sector Strategic Plan 2015-2020 recommended

Therapeutics and COVID-19: living guideline, Updated 16 September 2022
recommended

Clinical management and infection prevention and control for monkeypox
recommended

The National Tuberculosis Health Sector Strategic Plan 2015-2020
recommended